Treatment of Community-Acquired Native Valve Infective Endocarditis Before Pathogen Identification

This protocol covers empiric antibiotic management for community-acquired native valve infective endocarditis (NVE) and for late prosthetic valve infective endocarditis (PVE) — defined as onset 12 months or more after valve surgery — in the period before a causative pathogen has been microbiologically identified.

Clinical Scenario

The patient presents with infective endocarditis on a native valve acquired outside of a healthcare setting, or with prosthetic valve endocarditis classified as late-onset (≥12 months post-surgery). Empiric broad-spectrum therapy is required while blood culture and microbiological results are pending.

Treatment Approach (Partial Overview)

Empiric management relies on parenteral combination antibiotic therapy with ampicillin as the central agent, paired with a complementary second agent. Two regimen options are outlined in the full protocol, each with distinct companion drugs.

Full regimen selection, dosing, dosing intervals, route, and duration are available in the structured protocol below.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1093/eurheartj/ehad193

In patients with community-acquired NVE or late PVE (≥12 months post-surgery), ampicillin in combination with ceftriaxone or with (flu)cloxacillin and gentamicin should be considered using the following doses:

View source ↗